Houston, TX, United States

Time filter

Source Type

Patent
Base Pair Biotechnologies, Inc. | Date: 2016-10-22

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules.


Aptamers Market 2016- Aptus Biotech, NeoVentures Biotechnology, Aptamer Solutions, Base Pair Biotechnologies. A market study based on the  Aptamers market  across the globe, recently added to the repository of QY Market Research, is titled ‘Global Aptamers Market 2016’. The research report analyzes the historical as well as present performance of the global Aptamers market, and makes predictions on the future status of Aptamers market on the basis of this analysis. The report studies the market for Aptamers across the globe taking the existing industry chain, the import and export statistics in Aptamers market & dynamics of demand and supply of Aptamers into consideration. Aptamer Solutions Ltd. (U.K.) Aptus Biotech S.L. (Spain) Base Pair Biotechnologies, Inc. (U.S.) NeoVentures Biotechnology, Inc. (Canada) SomaLogic, Inc. (U.S.) TriLink BioTechnologies, Inc. (U.S.) Vivonics, Inc. (U.S.) The ' Aptamers 'research study covers each and every aspect of the Aptamers market globally, which starts from the definition of the Aptamers market and develops towards Aptamers market segmentations. Further, every segment of the Aptamers market is classified and analyzed on the basis of product types, application, and the end-use industries of the Aptamers market. The geographical segmentation of the Aptamers market has also been covered at length in this report. The competitive landscape of the global market for Aptamers is determined by evaluating the various market participants, production capacity, Aptamers market's production chain, and the revenue generated by each manufacturer in the Aptamers market worldwide. The global Aptamers market 2016 is also analyzed on the basis of product pricing, Aptamers production volume, data regarding demand and Aptamers supply, and the revenue garnered by the product. Various methodical tools such as investment returns, feasibility, and market attractiveness analysis has been used in the research to present a comprehensive study of the market for Aptamers across the globe.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2014

The human cytomegalovirus (CMV) is one of the most common intrauterine transmitted viral agents, leading to congenital CMV infection in three to ten newborns per thousand. Depending on the preexisting status of the mother, this infection leads to more or less severe symptoms and in about 2-6% the infected children die as a consequence of the infection. Beside this, sequelae occur in a number of infected children, mainly unit-rapid, point-of-care assay that could detect CMV DNA or proteins in urine or saliva would allow for immediate counseling and additional specimen collection for confirmatory testing, and would avoid having to create new laboratory infrastructure for widespread urine or saliva testing. Here we will develop a sensitive & selective assay that can be used in medium resource or clinic setting for both CMV proteins & DNA in urine. The assay will be based on aptamers and backscattering interferometry in an easy-to-use, rugged instrument. Combining these two technologies has major advantages with respect to speed of assay development & validation, sensitivity, simplicity & compatibility with urine or saliva. The final system will have sensitivity rivaling PCR but with the user simplicity of a lateral flow device.


Patent
Base Pair Biotechnologies, Inc. | Date: 2013-01-23

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. The present invention further relates to methods for generating, for example, functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. More than one or multiple targets as used herein may generally include different types of targets, and/or may also include a multitude of a singular type of targets at different conditions, such as, for example, temperature, pH, chemical environment, and/or any other appropriate conditions.


Patent
Base Pair Biotechnologies, Inc. | Date: 2012-10-15

The present invention relates to methods for generating functional biomolecules. In one exemplary aspect of the invention, generation of functional biomolecules may be performed against multiple targets simultaneously within a single system. In general, a plurality of targets may be disposed within in a single reaction volume and a library of biomolecules, such as a nucleic acid library, may be applied to the reaction volume. The members of the library that do not bind to any of the plurality of targets under given conditions may then be partitioned. The remaining members of the library may then be marked and/or tagged, such as to identify the particular target or targets to which the member of the library binds. The binding members of the library may then be isolated and, by virtue of the marking or tagging, be matched to a particular target or targets.


Patent
Base Pair Biotechnologies, Inc. | Date: 2014-04-21

Molecular probes to particular targets may be nucleic acids that may generally possess resistance to degradation when bound to a target molecule. For example, the molecular probes may be generally resistant to nuclease degradation when bound to their target molecules, and generally not resistant to nuclease degradation when unbound to their target molecules. This may be utilized, for example, to selectively degrade unbound molecular probes while preserving the bound molecular probes, which may thus serve as an indication of the presence of their target molecules in a sample.


Patent
Base Pair Biotechnologies, Inc. | Date: 2014-06-05

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules.


Patent
Base Pair Biotechnologies, Inc. | Date: 2014-06-05

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 199.56K | Year: 2013

The stated Phase I activities and expected deliverables of this SBIR Contract include: 1) Development of proof-of-concept technologies that reliably generate anti-peptide capture reagents that can immunoprecipitate the target peptides; 2) Demonstrate that the capture reagents developed can reproducibly immunoprecipitate the target peptides; 3) Work with the CPTC community, private and public sector to identify minimum characterization criteria for validation of the assays; 4) Generate affinity reagentsto at least ten proteotypic peptides and demonstrate high affinity, specificity and immunoprecipitation performance; 5) Make available to NCI sufficient reagents to perform 10 test runs for each of the ten peptides for independent evaluation; 6) Presentfindings to an NCI CPTC Evaluation Panel demonstrating how the capture reagents have improved cost effectiveness and throughput capabilities in production. PUBLIC HEALTH RELEVANCE


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 218.78K | Year: 2016

DESCRIPTION provided by applicant Neonatal and pediatric intensive care still involves performing painful needle punctures to obtain blood samples for routine clinical monitoring Pain management in the neonatal setting is often achieved by long term continuous intravenous infusion of morphine or related compounds It has become increasingly clear however that long term use of opioid compounds in neonates is likely to have significant deleterious neurological effects Unfortunately the very nature of neonates lower weight and incomplete and varied metabolic development complicates pharmacokinetic studies and modeling New analytical platforms are needed to enable studies of commonly used compounds in this patient population Non or minimally invasive microfluidic platforms with the ability to address multiple analytes in flexible manner have great promise in improving neonatal pain management and patient outcomes This project will apply a relatively new mode of detection backscattering interferometry BSI in conjunction with novel DNA aptamers binding agents to detect and quantify important opioids used for pain management in neonates as well as propofol an important agent used for general anesthesia We will also generate the necessary aptamers for detection of the urinary metabolites of these compounds The developed platform only requires microliter or less of urine and will enable studies and possibly personalized dosing of therapeutic compounds in neonates Because of our expertise to rapidly develop aptamers to small molecules in Phase II we will be in an excellent position to expand the menu of assays and translate them to the clinic with a recently developed benchtop BSI instrument PUBLIC HEALTH RELEVANCE Backscattering interferometry BSI is a recently developed technology for sensitive molecular detection developed by scientists at Vanderbilt University This project will develop a new system for rapid quantitation of pharmaceutical compounds and metabolites in the urine of newborns Because the system is microfluidic it requires less than microliter of sample and results are available in less than minute after sample introduction A new benchtop instrument has been recently developed which will allow us to rapidly translate the platform to the clinic or neonatal intensive care unit NICU in Phase II

Loading Base Pair Biotechnologies, Inc. collaborators
Loading Base Pair Biotechnologies, Inc. collaborators